Evidence map›Paper›PMID 39553702›Full record

ArticleEFSA journal. European Food Safety Authority2024

Re-evaluation of saccharin and its sodium, potassium and calcium salts (E 954) as food additives.

EFSA Panel on Food Additives and Flavourings (FAF), Laurence Castle, Monica Andreassen, Gabriele Aquilina, Maria Lourdes Bastos, Polly Boon, Biagio Fallico, Reginald FitzGerald, Maria Jose Frutos Fernandez, Bettina Grasl-Kraupp and 33 more

Abstract read
In one paragraph

Article in EFSA journal. European Food Safety Authority, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Safety assessment of the substance l-aspartic acid,EFSA journal. European Food Safety Authority · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Food Additives: Emerging Detrimental Roles on Gut Health.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

EFSA Panel on Food Additives and Flavourings (FAF)
Laurence Castle
Monica Andreassen
Gabriele Aquilina
Maria Lourdes Bastos
Polly Boon
Biagio Fallico
Reginald FitzGerald
Maria Jose Frutos Fernandez
Bettina Grasl-Kraupp
Ursula Gundert-Remy
Rainer Gürtler
Eric Houdeau
Marcin Kurek
Henriqueta Louro
Patricia Morales
Sabina Passamonti
Monika Batke
Ellen Bruzell
James Chipman
Karlien Cheyns
Riccardo Crebelli
Cristina Fortes
Peter Fürst
Thorhallur Halldorsson
Jean-Charles LeBlanc
Manuela Mirat
Oliver Lindtner
Alicja Mortensen
Evangelia Ntzani
Romina Shah
Heather Wallace
Matthew Wright
Stefania Barmaz
Consuelo Civitella
Petra Georgelova
Federica Lodi
Elena Mazzoli
Josef Rasinger
Ana Maria Rincon
Alexandra Tard
Panagiota Zakidou
Maged Younes

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This opinion deals with the re-evaluation of saccharin and its sodium, potassium and calcium salts (E 954) as food additives. Saccharin is the chemically manufactured compound 1,2-benzisothiazol-3(2H)-one-1,1-dioxide. Along with its sodium (Na), potassium (K) and calcium (Ca) salts, they are authorised as sweeteners (E 954). E 954 can be produced by two manufacturing methods i.e. Remsen-Fahlberg and Maumee. No analytical data on potential impurities were provided for products manufactured with the Maumee process; therefore, the Panel could only evaluate saccharins (E 954) manufactured with the Remsen-Fahlberg process. The Panel concluded that the newly available studies do not raise a concern for genotoxicity of E 954 and the saccharins impurities associated with the Remsen-Fahlberg manufacturing process. For the potential impurities associated with the Maumee process, a concern for genotoxicity was identified. The data set evaluated consisted of animals and human studies. The Panel considered appropriate to set a numerical acceptable daily intake (ADI) and considered the decrease in body weight in animal studies as the relevant endpoint for the derivation of a reference point. An ADI of 9 mg/kg body weight (bw) per day, expressed as free imide, was derived for saccharins (E 954). This ADI replaces the ADI of 5 mg /kg bw per day (expressed as sodium saccharin, corresponding to 3.8 mg /kg bw per day saccharin as free imide) established by the Scientific Committee on Food. The Panel considered the refined brand-loyal exposure assessment scenario the most appropriate exposure scenario for the risk assessment. The Panel noted that the P95 exposure estimates for chronic exposure to saccharins (E 954) were below the ADI. The Panel recommended the European Commission to consider the revision of the EU specifications of saccharin and its sodium, potassium and calcium salts (E 954).

Indexed as

E 954food additivepotassium and calcium saltssaccharin and its sodiumsweetener

Identifiers

PMID39553702
PMCPMC11565076

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.